Zydus Cadila Launches Third Salvo Against COVID-19 With Interferon
Vaccine Also Moving Towards Trials
Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.
You may also be interested in...
Coronavirus Update: Coalition Aims To Overcome 'Disjointed' COVID-19 Trials, Gilead's Open Label Criticized
NIH's Collins brings together coalition after months of behind-the-scenes work. Meanwhile, Gilead's remdesivir trials are the center of huge expectation and controversy.
Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.
Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.